ORPHA:99967
Myxoid/round cell liposarcoma
Also known as: MRCLS
Publications
718
82.9th percentile
Trials
14
Interventional, condition-specific
Researchers
1,264
Distinct authors in sample
Gene link
—
Readiness
4/6
Stages with a signal
Clinical definition (Orphanet)
Myxoid/round cell liposarcoma (MRCLS) is a type of liposarcoma (LS) mostly located in the limbs, with a variable behavior depending on the histological subtype. Both myxoid and round cell are distinct histological subtypes of LS.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0020561
- UMLS:C0545074
Additional Mondo synonyms (1)
myxoid/round-cell liposarcoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
4/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
718 matched papers (481 in last 10 years) Source
- Phenotype characterisedPresent
4 HPO annotations (e.g. Myxoid liposarcoma; Subcutaneous nodule; Abdominal pain) Source
- Animal modelPresent
1 genotype model (Mus musculus) Source
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
14 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
4
Associated phenotypes · MONDO:0020561
- Myxoid liposarcoma
- Subcutaneous nodule
- Abdominal pain
- Gastrointestinal dysmotility
Animal models (Monarch / Alliance)
1
Model associations linked to this Mondo ID
- Trp53tm1Tyj/Trp53tm1Tyj Tg(Prrx1-FUS/DDIT3)1Mete/0 [background:] involves: 129S2/SvPas * C57BL/6 * CBA·MGI:5430234·Mus musculus
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
7
Drugs / clinical candidates · MONDO_0020561
- CYCLOPHOSPHAMIDE·phase 2
- FLUDARABINE·phase 2
- LETETRESGENE AUTOLEUCEL·phase 2
- FLUDARABINE PHOSPHATE·phase 1
- INTERFERON GAMMA-1B·early phase 1
- NOGAPENDEKIN ALFA INBAKICEPT·early phase 1
- PEMBROLIZUMAB·phase 1 2
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
718
718 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
718 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
481 in the last 10 years · high confidence · 82.9th percentile (publications denominator)
Phrase hits: 718 · MeSH hits: 0
Who's working on it?
1,264
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Pollack SM14 papers · 2026
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Papers in Europe PMC - 02Jones RL10 papers · 2025
Sarcoma Unit, Royal Marsden Hospital NHS Trust and Institute of Cancer Research, London SW3 6JJ, UK.
Papers in Europe PMC - 03Wang X8 papers · 2026
Department of Gynecologic Oncology, Gynecology and Obstetrics Centre, The First Hospital of Jilin University, Changchun, China.
Papers in Europe PMC - 04Somaiah N7 papers · 2026
Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 0450, Houston, TX 77030, USA.
Papers in Europe PMC - 05Wang W7 papers · 2026
Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Papers in Europe PMC - 06Wu G6 papers · 2022
Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Papers in Europe PMC - 07Blay JY5 papers · 2026
Department of Medical Oncology, Centre Léon Bérard, University Claude Bernard Lyon I, Lyon, France.
Papers in Europe PMC - 08Cranmer LD5 papers · 2024
Department of Medical Oncology, University of Washington, Seattle, WA 98195, USA.
Papers in Europe PMC - 09Druta M5 papers · 2025
Medical Oncology, Moffitt Cancer Center, Tampa, FL, United States.
Papers in Europe PMC - 10Wu T5 papers · 2022
Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
14
interventional trials for this specific condition
14 interventional trials matched this specific condition name; 2 currently recruiting in our sample. 120 trials are registered for liposarcoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
14 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 93.7th percentile).
high confidence · 93.7th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
14 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07261657·RECRUITING·N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy
Not reviewed·Conditions: Myxoid Liposarcoma · Round Cell Liposarcoma · Synovial Sarcoma·Matched via name phrase
- NCT06083883·RECRUITING·Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1
Not reviewed·Conditions: Synovial Sarcoma · Myxoid/Round Cell Liposarcoma·Matched via name phrase
Broader category: liposarcoma
120
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06498648·RECRUITING·Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
Not reviewed·Conditions: Advanced Dedifferentiated Liposarcoma · Advanced Leiomyosarcoma · Advanced Soft Tissue Sarcoma · Metastatic Dedifferentiated Liposarcoma·Matched via name phrase
- NCT06957431·RECRUITING·Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Not reviewed·Conditions: Advanced Leiomyosarcoma · Adipocytic Sarcoma · Advanced Liposarcoma·Matched via name phrase
- NCT07224568·NOT YET RECRUITING·Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors
Not reviewed·Conditions: Solid Tumor (Excluding CNS) · Hepatocellular Carcinoma · Liver Cell Carcinoma · Liposarcoma·Matched via name phrase
- NCT06389799·RECRUITING·A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)
Not reviewed·Conditions: Dedifferentiated Liposarcoma·Matched via name phrase
- NCT05492682·RECRUITING·START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Not reviewed·Conditions: Melanoma (Skin) · Triple-Negative Breast Cancer · Non-Small Cell Lung Cancer · Synovial Sarcoma·Matched via name phrase
- NCT05711615·RECRUITING·Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Not reviewed·Conditions: Metastatic Dedifferentiated Liposarcoma · Metastatic Leiomyosarcoma · Metastatic Myxofibrosarcoma · Metastatic Sarcoma·Matched via name phrase
- NCT04785196·RECRUITING·APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Not reviewed·Conditions: Liposarcoma · Advanced Solid Tumor·Matched via name phrase
- NCT07686367·NOT YET RECRUITING·Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers
Not reviewed·Conditions: Metastatic Myxoid Liposarcoma · Metastatic Synovial Sarcoma · Unresectable Myxoid Liposarcoma · Unresectable Synovial Sarcoma·Matched via name phrase
- NCT07169344·RECRUITING·Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma
Not reviewed·Conditions: Soft Tissue Sarcoma (Excluding GIST) · Soft Tissue Sarcoma Adult · Soft Tissue Sarcoma of the Trunk and Extremities · Synovial Sarcomas·Matched via name phrase
- NCT06422806·RECRUITING·Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Not reviewed·Conditions: Metastatic Dedifferentiated Liposarcoma · Metastatic Undifferentiated Pleomorphic Sarcoma · Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 · Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8·Matched via name phrase
- NCT06025747·RECRUITING·A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for Liposarcomas
Not reviewed·Conditions: Retroperitoneal Sarcoma · Liposarcoma · Dedifferentiated Liposarcoma·Matched via name phrase
- NCT06849986·RECRUITING·IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
Not reviewed·Conditions: Soft Tissue Sarcomas · Angiosarcoma · Fibrosarcoma · Leiomyosarcoma·Matched via name phrase
- NCT04224064·RECRUITING·Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas
Not reviewed·Conditions: Liposarcoma · Atypical Lipomatous Tumor·Matched via name phrase
- NCT07173972·RECRUITING·Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.
Not reviewed·Conditions: Soft Tissue Sarcoma (STS) · Soft Tissue Sarcoma Adult · Soft Tissue Sarcoma of the Trunk and Extremities · Synovial Sarcomas·Matched via name phrase
- NCT06843967·RECRUITING·A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Not reviewed·Conditions: Well Differentiated Liposarcoma · Dedifferentiated Liposarcoma · Liposarcoma · Myxoid Liposarcoma·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 5 · after dedupe 5 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 5 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (5)
- ctis·2024-516787-28-00·Authorised·EPITOME-1015-I: A phase I study to investigate the safety and tolerability of MDG1015 in patients with epithelial ovarian cancer, gastroesophageal adenocarcinoma, round cell liposarcoma and/or synovial sarcoma
skipped — LLM skipped (--skip-llm)
- ctis·2024-513033-21-00·Authorised, recruiting·Long-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies
skipped — LLM skipped (--skip-llm)
- ctis·2024-513032-14-00·Cancelled·Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
skipped — LLM skipped (--skip-llm)
- ctis·2024-512847-21-00·Expired·A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
(SPEARHEAD 1 STUDY)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15110275·No longer recruiting·Cell therapy clinical trial of BOXR1030 in GPC3 positive liver, squamous lung, Merkel cell cancer, and myxoid/round cell liposarcoma
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Myxoid/round cell liposarcoma — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Myxoid/round cell liposarcoma" OR "MRCLS" OR "myxoid/round-cell liposarcoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Myxoid/round cell liposarcoma" OR "MRCLS" OR "myxoid/round-cell liposarcoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 14 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"liposarcoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T06:48:13.460Z
